New NBS 6 system order for Nexstim from USA
Translation: Original published in Finnish on 7/6/2026 at 9:04 am EEST.
Nexstim announced on Friday that it had received an order for an NBS 6 system from a new customer in the United States. The system is used for therapy applications, such as the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The news is a positive continuation of the larger device order announced in June and supports our growth forecasts.
The US is a key market for Nexstim in the therapy business, and winning a new customer supports the company's growth strategy. We expect the company's full-year 2026 revenue to grow by just under 16% to 12.7 MEUR, which necessitates a steady flow of equipment orders throughout the year.
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read more on company pageKey Estimate Figures14.05
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 11.0 | 12.7 | 16.1 |
| growth-% | 25.5 % | 15.7 % | 26.8 % |
| EBIT (adj.) | 0.6 | 1.2 | 2.3 |
| EBIT-% (adj.) | 5.8 % | 9.5 % | 14.1 % |
| EPS (adj.) | 0.08 | 0.12 | 0.27 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | 123.3 | 78.9 | 36.7 |
| EV/EBITDA | 43.0 | 31.3 | 20.4 |
Forum discussions
